CML & PH+ All: There is so much more to know CML & PH+ All: There is so much more to know Explore

The think test treat programme was initiated by Incyte to raise awareness of the importance of regular and sensitive BCR-ABL1 monitoring and guidance-compliant mutation testing in patients with PH+ LEUKAEMIAS

Think

about how regular monitoring can help you identify patients
at risk and help guide your therapeutic treatment decisions1-5

Test

CML patients with resistance/failure to current treatment, always when switching TKI, and Ph+ ALL patients with persistent or increasing MRD1,6-8

Treat

patients with resistance/failure to current treatment with the most appropriate TKI according to prior treatment and mutation testing results1,6-10

Incyte Incyte is committed to making a difference in the way the community is monitoring and performing mutation testing for patients with CML and PH+ All

INCYTE INITIATED THE THINK TEST TREAT
PROGRAMME TO:

  • Identify and address barriers to optimal BCR-ABL1 monitoring and mutation testing across Europe
  • Raise awareness and educate about how BCR-ABL1 monitoring and sensitive mutation testing can guide clinical decision-making in CML and Ph+ ALL

FIND OUT MORE WITH OUR EDUCATIONAL RESOURCES

All AEs should be reported to the Global Medical Information Call Center by phone: +800 000 27423
(for local numbers see www.incyteglobalmedicalinformation.com/report-adverse-event.aspx).
Alternatively, you can report AEs by email: eumedinfo@incyte.com

For more information, please contact Incyte Medical Information: eumedinfo@incyte.com